子宫内膜癌腹腔冲洗液分析:panel测序体细胞突变检测与传统细胞学的比较
本研究收集2018年9月至2019年7月间21例新诊断子宫内膜癌患者的腹腔冲洗液,采用靶向468个癌症相关基因的panel测序检测肿瘤突变,并与传统细胞学比较。细胞学阳性8例(38%),分子分析在18/21(86%)冲洗液中检出肿瘤突变;细胞学阴性或可疑者中77%(10/13)检出突变。作者认为panel测序检测腹腔冲洗液突变可行。
要点
- 21例子宫内膜癌患者腹腔冲洗液,细胞学阳性8例(38%),分子分析检出肿瘤突变18例(86%)。
- 细胞学阴性或可疑的13例中,10例(77%)分子分析检出肿瘤突变。
- 10例复发患者中,细胞学阳性5例(50%),分子分析检出突变9例(90%)。
核心结论
- 采用panel测序对子宫内膜癌腹腔冲洗液进行突变分析是可行的。
- 相当一部分细胞学阴性或可疑的冲洗液可检出肿瘤突变。
研究设计与样本
- 研究纳入2018年9月至2019年7月间21例活检确诊的新诊断子宫内膜癌患者,覆盖不同疾病分期。
- 收集腹腔冲洗液、原发子宫内膜癌组织和正常DNA样本,进行靶向468个癌症相关基因的二代测序。
- 测序结果与细胞学分析进行比较。
主要发现
- 21例中细胞学阳性8例(38%),阴性7例(33%),可疑或罕见非典型细胞6例(29%)。
- 分子分析在18/21(86%)的腹腔冲洗液中检出肿瘤突变。
- 11/21(52%)样本细胞学与分子分析结果一致,所有细胞学阳性结果均经分子分析确认。
- 细胞学阴性或可疑的病例中,77%(10/13)在冲洗液中检出肿瘤突变;细胞学阴性者5/7(71%)分子分析阳性,可疑者5/6(83%)检出突变。
- 10例复发患者中,无论分期,细胞学阳性5/10(50%),分子分析检出突变9/10(90%)。
临床怎么用
- 作者认为,采用panel测序对子宫内膜癌腹腔冲洗液进行突变分析是可行的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The prognostic significance of positive pelvic washings in endometrial cancer (EC) remains unknown, and little data exist regarding washings as a source of genetic information in relation to a patient's tumor. We sought to assess the feasibility of identifying EC mutations in peritoneal washings. METHODS: Peritoneal washings from 21 biopsy-confirmed newly diagnosed patients with EC across disease stages between 09/2018 and 07/2019 were collected. Peritoneal washings, primary EC, and normal DNA samples were subjected to next-generation sequencing targeting 468 cancer-related genes. Sequencing results were compared to cytological analysis. RESULTS: For the 21 EC cases included, cytology found 8 (38 %) of the peritoneal washings as positive, 7 (33 %) as negative, and 6 (29 %) as suspicious or rare-atypical cells. Based on molecular analysis, tumor mutations (TMs) were detected in 18/21 (86 %) of peritoneal washings. Overall, 11/21 (52 %) samples demonstrated concordant results between cytologic and molecular analysis, and all positive cytologic results were confirmed with molecular analysis. However, of cases with negative or suspicious cytology results, 77 % (10/13) were found to have TMs in washings. Five patients with negative cytology were positive on molecular analysis (5/7, 71 %), and 5 patients with suspicious washings demonstrated TMs (5/6, 83 %). Of the 10 EC patients who developed recurrences, regardless of stage, 5/10 (50 %) patients had positive cytology, whereas 9/10 (90 %) had TMs based on molecular analysis. CONCLUSIONS: Mutational analysis of peritoneal washings using panel sequencing in EC is feasible. A substantial subset of patients with cytology-negative or suspicious washings had TMs detected.
引用
- Byrne ME, Selenica P, Dessources K, et al. Peritoneal washings analysis in endometrial cancer: Comparison of somatic mutation detection with panel sequencing and traditional cytology. Gynecol Oncol. 2025. PMID: 40347837. doi:10.1016/j.ygyno.2025.05.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。